Kevin Bitterman Sells 129 Shares of Disc Medicine (NASDAQ:IRON) Stock

September 4, 2026 by InsiderTrades.com

Key Points

Director Kevin Bitterman sold 49,164 Disc Medicine shares at an average price of $80.17, generating approximately $3.94 million. The sale reduced his direct holdings by 78.46% and was conducted under a pre-arranged Rule 10b5-1 trading plan.
Disc Medicine shares opened at $79.37, with a market capitalization of approximately $3.05 billion. The company reported a quarterly loss of $1.54 per share, which was better than analysts’ expected loss of $1.71.
Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $107.70; however, Wall Street Zen downgraded the stock to “sell.” Institutional investors and hedge funds own approximately 83.7% of the company.

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Kevin Bitterman sold 129 shares of the business's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $79.95, for a total value of $10,313.55. Following the completion of the transaction, the director owned 14,012 shares in the company, valued at $1,120,259.40. The trade was a 0.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Bitterman also recently made the following trade(s):

On Thursday, September 3rd, Kevin Bitterman sold 5,203 shares of Disc Medicine stock. The shares were sold at an average price of $79.98, for a total value of $416,135.94.
On Wednesday, September 2nd, Kevin Bitterman sold 49,164 shares of Disc Medicine stock. The stock was sold at an average price of $80.17, for a total value of $3,941,477.88.

Disc Medicine Price Performance

IRON opened at $79.37 on Friday. The firm has a market cap of $3.05 billion, a P/E ratio of -12.06 and a beta of 0.97. The firm has a 50-day moving average of $77.67 and a 200 day moving average of $70.32. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.71) by $0.17. On average, research analysts expect that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Institutional Trading of Disc Medicine

Several hedge funds and other institutional investors have recently modified their holdings of the business. NEXTBio Capital Management LP bought a new stake in shares of Disc Medicine during the 4th quarter valued at $3,397,000. DNB Asset Management AS grew its stake in Disc Medicine by 1,425.8% during the fourth quarter. DNB Asset Management AS now owns 84,255 shares of the company's stock valued at $6,691,000 after acquiring an additional 78,733 shares in the last quarter. Eagle Health Investments LP bought a new stake in Disc Medicine during the 4th quarter worth approximately $2,152,000. Vanguard Group Inc. increased its holdings in Disc Medicine by 22.1% during the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock worth $140,371,000 after acquiring an additional 319,621 shares during the period. Finally, BlackRock Inc. bought a new position in Disc Medicine in the 2nd quarter valued at $180,502,000. Institutional investors own 83.70% of the company's stock.

Key Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

Positive Sentiment: Wedbush raised its price target for Disc Medicine from $88 to $100 and maintained an “outperform” rating. The new target implies approximately 26% upside from the referenced $79.37 price, signaling continued analyst confidence in the company’s prospects. Benzinga analyst price target report
Neutral Sentiment: Disc Medicine announced that management will participate in fireside chats at four upcoming investor conferences. These events could provide updates on the company’s hematology pipeline, but no new clinical or financial information was disclosed in the announcement. Disc Medicine investor conference announcement
Negative Sentiment: Director Kevin Bitterman sold a combined 54,496 shares of Disc Medicine for approximately $4.37 million across transactions dated September 1–3. The sales reduced his position by roughly 80% overall, which may concern investors about insider conviction. However, the trades were executed under a pre-arranged Rule 10b5-1 plan, meaning they were scheduled in advance and do not necessarily reflect a current change in his outlook. SEC insider trading filing
Negative Sentiment: Rosen Law Firm announced an investigation into potential securities claims involving allegations that Disc Medicine may have issued materially misleading business information. The announcement increases headline and litigation risk, although it does not establish wrongdoing or guarantee that a lawsuit will be filed. Rosen Law Firm investigation announcement

Analyst Ratings Changes

A number of research firms recently commented on IRON. HC Wainwright lifted their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Wedbush raised their target price on Disc Medicine from $88.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday. Wall Street Zen lowered Disc Medicine from a "hold" rating to a "sell" rating in a research note on Saturday, August 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Disc Medicine in a research note on Friday, July 17th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Disc Medicine in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $107.70.

Read Our Latest Research Report on IRON

Disc Medicine Company Profile

(Get Free Report)

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.